IPO registrations (S-1, F-1) · Registrants
MESOBLAST LTD
- SEC CIK
- 1345099 · filings on EDGAR ↗
- Registration
- Form F-1, first filed 2015-11-02, last 2015-11-09; 1 initial registration, 2 amendments
- Outcome
- Final prospectus filed 2015-11-13; declared effective 2015-11-12
- Industry (SIC)
- Biological Products, (No Diagnostic Substances) 2836
- Incorporated in
- C3
- Business address
- LEVEL 38, 55 COLLINS STREET, Melbourne, Victoria, C3 3000
- Ticker
- MESO, MEOBF (Nasdaq, OTC)
- EDGAR entity type
- other
- Insiders and CEO pay
- MESOBLAST LTD on the corporate pages
Offering terms
- Final price
- $8.00 per ADS (424B4 filed 2015-11-13, an initial public offering)
- Shares sold
- 7,479,617
- Gross proceeds
- $59,836,936 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol MESO
- Lead underwriters
- J.P. Morgan; Credit Suisse
- Syndicate
- Ladenburg Thalmann; Maxim Group
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Form D issuer: MESOBLAST LTD EXACT (CIK (EXACT))
- SEC filer: MESOBLAST LTD EXACT (CIK (EXACT))
Filings 7
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2015-11-02 | F-1 | F-1 (foreign registration) | MESOBLAST LTD | 0001193125-15-361222 ↗ |
| 2015-11-06 | F-1/A | F-1/A (amendment) | MESOBLAST LTD | 0001193125-15-370416 ↗ |
| 2015-11-09 | F-1/A | F-1/A (amendment) | MESOBLAST LTD | 0001193125-15-371570 ↗ |
| 2015-11-12 | F-1MEF | F-1MEF (added securities) | MESOBLAST LTD | 0001193125-15-376107 ↗ |
| 2015-11-12 | EFFECT | EFFECT (declared effective) | MESOBLAST LTD | 9999999995-15-003041 ↗ |
| 2015-11-13 | 424B4 | 424B4 (final prospectus) | MESOBLAST LTD | 0001193125-15-377091 ↗ |
| 2017-07-21 | EFFECT | EFFECT (declared effective) | MESOBLAST LTD | 9999999995-17-001898 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2015-11-09 | F-1/A | registration statement | 15,298,837 | - | 0 | primary document; shares headline | document ↗ | |||
| 2015-11-13 | 424B4 | final prospectus | $8.00 | 7,479,617 | $59,836,936 | Nasdaq MESO | 4 | primary document; price sentence, shares headline, proceeds table, cover names 4 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| George Gregory | Director; Director,TenPercentOwner | 4 | 2026 | ||
| BELL JANE CATHERINE | Director | 1 | 2026 | ||
| FACCHINA PHILIP JAMES | Director | 1 | 2026 | ||
| KRAUSE PHILIP R. | Director | 1 | 2026 | ||
| OBRIEN JAMES MICHAEL | Officer | Chief Financial Officer | 2 | 2026 | |
| ROSE ERIC ALLEN | Director,Officer | Chief Medical Officer,Director | 1 | 2026 | |
| BURNS WILLIAM MURRAY | Director | 1 | 2026 | ||
| Itescu Silviu | Director,Officer | CEO and Managing Director | 2 | 2026 | |
| COBLEY LYNETTE ELIZABETH | Director | 1 | 2026 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2020-05-26 | MESOBLAST LTD | Biotechnology | $6,498,939 | $6,498,939 | 2 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Form D issuer | MESOBLAST LTD | Form D private offerings | CIK (EXACT) | |
| SEC filer | MESOBLAST LTD | SEC filers (EDGAR) | CIK (EXACT) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Biological Products, (No Diagnostic Substances), C3 first:
- GENETIC TECHNOLOGIES LTD C3
- BioNTech SE 2M
- Immatics N.V. 2M
- CHEMOKINE THERAPEUTICS CORP A1
- Fusion Pharmaceuticals Inc. A6
- CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. AZ
- Ablynx NV C9
- SANGAMO THERAPEUTICS, INC CA
- GENITOPE CORP CA
- ABGENIX INC CA
In other datasets, the same topic (Health) in C3:
- Form D issuer: Botanix Pharmaceuticals Ltd. (Form D private offerings)
Interests: Biological Products, (No Diagnostic Substances) · Health